S
5.04
-0.03 (-0.59%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Bullish |
| Biotechnology (Global) | Bullish | Bullish | |
| Stock | Syros Pharmaceuticals, Inc. | Bullish | Bearish |
|
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bain Capital Life Sciences Investors, Llc | 31 Dec 2023 | 2,749,808 |
| Artal Group S.A. | 31 Dec 2023 | 2,505,013 |
| Samsara Biocapital, Llc | 31 Dec 2023 | 1,786,427 |
| Avidity Partners Management Lp | 31 Dec 2023 | 1,673,538 |
| Blue Owl Capital Holdings Lp | 31 Dec 2023 | 1,493,252 |
| Chi Advisors Llc | 30 Sep 2023 | 1,299,359 |
| Flagship Pioneering Inc. | 31 Dec 2023 | 1,293,848 |
| Deep Track Capital, Lp | 31 Dec 2023 | 828,485 |
| Opaleye Management Inc. | 31 Dec 2023 | 359,370 |
| Omega Fund Management, Llc | 31 Dec 2023 | 251,270 |
| 52 Weeks Range |
2.09 - 8.17
|
|
| Price Target Range | ||
| High | 15.00 (HC Wainwright & Co., 197.62%) | Buy |
| Median | 14.00 (177.78%) | |
| Low | 13.00 (Piper Sandler, 157.94%) | Overweight |
| Average | 14.00 (177.78%) | |
| Total | 1 Overweight, 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 03 Apr 2024 | 13.00 (157.94%) | Overweight | 4.98 |
| HC Wainwright & Co. | 01 Apr 2024 | 15.00 (197.62%) | Buy | 5.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Apr 2024 | Announcement | Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression |
| 02 Apr 2024 | Announcement | Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 27 Mar 2024 | Announcement | Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update |
| 25 Mar 2024 | Announcement | Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial |
| 20 Mar 2024 | Announcement | Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024 |
| 27 Feb 2024 | Announcement | Syros to Participate in TD Cowen 44th Annual Health Care Conference |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |